Even with these considerations, it is emphasized that targeting CLDN4 is an attractive therapeutic approach that offers pleiotropic benefits, including cancer cytotoxicity, reprogramming tumor microenvironments, and improvement of drug delivery. Here, CLDN4 is linked to neoplasm.